Hologic, Inc. (NASDAQ:HOLX) Shares Sold by ING Groep NV

ING Groep NV decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 71.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,121 shares of the medical equipment provider’s stock after selling 82,283 shares during the quarter. ING Groep NV’s holdings in Hologic were worth $2,698,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Empowered Funds LLC bought a new stake in Hologic during the first quarter valued at $234,000. Banco Santander S.A. bought a new stake in shares of Hologic during the 1st quarter valued at about $344,000. Mitsubishi UFJ Trust & Banking Corp raised its stake in Hologic by 0.4% during the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 292,378 shares of the medical equipment provider’s stock worth $22,490,000 after acquiring an additional 1,136 shares during the period. Intech Investment Management LLC lifted its holdings in Hologic by 4.3% in the first quarter. Intech Investment Management LLC now owns 40,687 shares of the medical equipment provider’s stock worth $3,172,000 after acquiring an additional 1,667 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Hologic by 11,074.7% during the first quarter. Acadian Asset Management LLC now owns 179,019 shares of the medical equipment provider’s stock valued at $13,947,000 after purchasing an additional 177,417 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on HOLX shares. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and cut their price target for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Mizuho reduced their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Royal Bank of Canada increased their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Leerink Partners reduced their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $78.60 on Friday. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a fifty day moving average price of $80.71 and a two-hundred day moving average price of $78.25. The firm has a market cap of $18.26 billion, a P/E ratio of 23.60, a PEG ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the company earned $0.89 earnings per share. Hologic’s revenue was up 4.5% compared to the same quarter last year. Research analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.